Green Journal publishes study showing leva “significantly improved” symptoms of urinary incontinence in women versus Kegel exercises alone

by Chris Barrett | Mar 11, 2022 | Press Releases

Journal of the American College of Obstetricians and Gynecologists (ACOG) publishes randomized controlled superiority trial showing leva’s efficacy in treating UI vs. performing Kegels alone.     BOSTON, March 11, 2022 /PRNewswire/ — Renovia Inc....

Capital Women’s Care to offer leva to patients across 55 locations in Maryland, Virginia, and Washington DC

by Chris Barrett | Mar 8, 2022 | Press Releases

BOSTON, March 7, 2022  /PRNewswire/ — Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that Capital Women’s Care is recommending the leva® Pelvic Health System...

Healthcare Technology Report announces their Top 25 Women Leaders in Medical Devices of 2022

by Chris Barrett | Jan 14, 2022 | Press Releases

The Healthcare Technology Report is pleased to announce The Top 25 Women Leaders in Medical Devices of 2022. With the medical device industry advancing at an unprecedented rate, new and exciting developments in robotics, materials science, analytics, and other...

Renovia receives 2021 Excellence Award for leva

by Chris Barrett | Jan 6, 2022 | Press Releases

Global award for Research and Development recognizes Renovia’s commitment to generating the highest quality data supporting leva as effective treatment for urinary incontinence   BOSTON, Jan. 6, 2022 /PRNewswire/ — Renovia Inc. (“Renovia”), a...

Published study supports leva® Pelvic Health System’s potential to improve fecal incontinence symptoms

by Chris Barrett | Dec 22, 2021 | Press Releases

BOSTON, Dec. 21, 2021 /PRNewswire/ — Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced that Neurourology and Urodynamics, the official journal of the Society for...

Renovia receives Breakthrough Device Designation for leva® Digital Therapeutic as first-line treatment for chronic fecal incontinence

by Renovia | Oct 29, 2021 | Press Releases

Boston, Mass—October 29, 2021—Renovia Inc. (“Renovia”), a women-led company that develops digital therapeutics for female pelvic floor disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the leva®...